OK HB3834

Creates the Oklahoma Breakthrough Therapy Act to establish a framework for ibogaine clinical trials seeking FDA approval, requiring drug developers to have existing agreements with at least one other state and submit detailed trial designs, protocols, and financial disclosures

Requires drug developers to match the state's investment with equal funding and conduct trials within Oklahoma using in-state clinicians, facilities, and participants to the maximum extent possible

Mandates post-FDA approval plans for broad patient access, including priority treatment for Oklahoma residents, third-party payor approval, access programs for uninsured and low-income individuals, and provider training

Establishes an Ibogaine Intellectual Property Account in the State Treasurer's Office to receive the state's proportional share of commercialization proceeds, with funds restricted to programs benefiting populations with conditions treatable by ibogaine (traumatic brain injury, opioid use disorder, substance use disorders, neurological/mental health disorders)

Protects medical professionals licensed in Oklahoma from adverse licensing action for recommending ibogaine therapy services, with an effective date of November 1, 2026